Genmab — Januar 2019
-
-
Godmorgen. Uha.det er grimt at sidde på toppen af sådan en udvikling. Jeg har desværre også prøvet det
-
can't see anything new really in the Novartis report, confirmation that - the Phase III program for
OMB157 in relapsing MS
is fully enrolled and is on track for completion in 2019.
In addition, a registration study for Japan was initiated
in March 2018. -
Ang Novartis, så har begge ASCLEPIOS studier primary completion i maj måned
-
(not a Genmab specific article:)
Following the M&A money, by phase and therapy area - http://www.evaluate.com/vantage/articles/data-insights/ma/following-ma-money-phase-and-therapy-area -
Tak Sukker.
-
)
1H'19 Clinical data Darzalex + RVd 1L MM ↑↑/↓↓↓ Phase II data from the GRIFFIN trial of Darzalex plus RVd vs. RVd
Mid’19 Clinical data Ofatumumab r/r MS ↑↑/↓↓ Phase III pivotal topline data from ASCLEPIOS I & II in MS
Mid’19 Clinical data Darzalex r/r MM ↑↑/↓↓↓ Phase III data from the COLUMBA study of SubQ vs. IV Darzalex -
Tak for M&A artikel EL. Interessant sammenholdning over tid og udviklingsfase
-
Yup. We’ve seen this before. Could be BlackRock reducing further and depressing the price in the process. On the other side there is usually a jump
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind